NCT07907653
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (20)
Show 15 moreShow less
Arms and interventions
Neoadjuvant treatment: deutenzalutamide 80 mg orally once daily plus androgen deprivation therapy (ADT) for 24 weeks, with docetaxel 60 mg/m2 intravenously every 3 weeks for 6 cycles. Prednisone acetate 5 mg orally twice daily is given during docetaxel treatment, with subsequent tapering/discontinuation according to the protocol. When medically appropriate, participants undergo radical prostatectomy with pelvic lymph node dissection approximately 2 weeks after neoadjuvant treatment. After adequate postoperative recovery, deutenzalutamide is resumed at the last tolerated dose with ADT for 24 weeks, starting approximately 4 weeks after surgery. No postoperative docetaxel is given. ADT continues throughout for a total of at least 13 months. Dose modifications and treatment interruptions follow the protocol.
Drugs: Deutenzalutamide, Docetaxel, ADT
Sites
1 site in 1 country
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangzhou, Guangdong, China